- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05379114
Comparative Study for the Evaluation of a New Medical Device on the Treatment of Head Lice Infestation
Comparative, Monocentric Study for the Evaluation of the Non-inferiority of a New Medical Device on the Treatment of Head Lice Infestation
Pediculosis capitis or head lice infestation is a human medical condition caused by the infestation of the hair by the parasitic insect Pediculus humanus capitis (human head lice). The most common symptom of infestation is pruritus (itching) on the head which normally intensifies 3 to 4 weeks after the initial infestation.
The test item has been developed with the ambition to offer a complete head lice treatment, whilst also offering ultimate convenience in use - making treatment of head lice infestation easy, and effective in few minutes.
The objectives of this clinical study are to assess the efficacy and the safety of a new Medical Device for lice infestation treatment compared to a comparator device, already in market.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Céline Lhéritier
- Phone Number: +33 (0)6 71 32 33 20
- Email: clh@dermscan.com
Study Locations
-
-
-
Quatre Bornes, Mauritius
- Recruiting
- Céline Lhéritier
-
Contact:
- Céline Lhéritier
- Phone Number: +33671323320
- Email: clh@dermscan.com
-
Principal Investigator:
- Aslham DOARIKA, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy subject;
- Sex: male or female;
- Age: 2 years and above;
- Subject with a slight to moderate lice infestation
- Subjects with various hair type (from 1 to 3C - hair scale) and hair length (from short to mid length hair, not exceeding shoulder)
- Documented oral informed consent for all subjects, including minors, given freely and expressly before the start of the study
- Written informed consent for subjects ≥18 years or legal guardian for subjects< 18 years given freely and expressly before start of the study;
- Written assent for subjects ≥12 to <18 years.
- Subject/Subject's legal guardian is psychologically able to understand the study related information and to give written informed consent;
- Females of childbearing potential must have a negative pregnancy test before the beginning of the study
Exclusion Criteria:
In terms of population
- Pregnant (confirmed by pregnancy test for women of childbearing potential) or nursing woman or planning a pregnancy during the study;
- Subject who had been deprived of their freedom by administrative or legal decision or adult subject who is under guardianship;
- Subject in a social or sanitary establishment;
- Subject in an exclusion period from a previous study or who is currently participating to another study on hair/scalp or who participated to another clinical study on hair/scalp within 3 months before first visit.
- Subject suspected to be non-compliant according to the Investigator's judgment.
- Subject with curly or frizzy hair (type 4a to 4c in the hair type scale above)
- Subject with hair length below the shoulder.
Subjects with more than 24 lice on the head
In terms of associated pathology
- Subject suffering from a severe or progressive disease or any other pathology that may interfere with the evaluation of the study results.
- Subject with a cutaneous disease on the studied zone (scalp and hair).
- Subject with severe scratches or open wounds/skin damages on the scalp (lice bites allowed however).
- Subject with a known or suspected allergy to any of the components/materials of the investigational or comparator devices, anti-lice comb or post-treatment shampoo.
- Subject who has diabetes (type 1 or 2).
Subject with known or suspected immune deficiency or autoimmune disease.
Relating to previous or ongoing treatment
Subject undergoing a topical treatment on the test area or a systemic treatment with :
- anti-inflammatory medication and/or anti-histamines during the previous 2 weeks and during the study;
- corticosteroids during the 2 previous weeks and during the study;
- retinoids and/or immunosuppressors during the 3 previous months and during the study;
- any medication stabilized for less than one month.
- Subject who received an anti-lice treatment in the previous 2 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: INVESTIGATIONAL DEVICE
new medical device for the treatment of head lice infestation: Paranix ®
|
new medical device for the treatment of head lice infestation: Paranix ®
|
Active Comparator: COMPARATOR DEVICE
dimethicone based head lice treatment (medical device class 1) already in market in europe: Pouxit ®
|
well established medical device for the treatment of head lice infestation (dimethicone based) - Pouxit ®
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cure Rate after complete treatment
Time Frame: day 7
|
The cure rate is defined as the rate of subjects having no live lice on scalp 7 days after the last application of the product.
|
day 7
|
Cure Rate after complete treatment
Time Frame: day 14
|
The cure rate is defined as the rate of subjects having no live lice on scalp 7 days after the last application of the product.
|
day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cure rate after one dose of Investigational device (ID)
Time Frame: Day 7
|
Comparison of the percentage of subjects cured after one dose of the investigational device compared to the percentage of subjects cured with two doses of the comparator device.
|
Day 7
|
Dead and live lice/nymphs and number of eggs after combing
Time Frame: Day 0 and Day 7 if applicable
|
Number of dead and live lice/nymphs and number of eggs collected on the anti-lice comb after treatment
|
Day 0 and Day 7 if applicable
|
Live lice and nymphs, after application
Time Frame: Day 1 and Day 8 if applicable
|
Evaluation of the presence of live lice and nymphs, for both groups, without combing on scalp
|
Day 1 and Day 8 if applicable
|
Number of participants with treatment-related adverse events as assessed by investigator
Time Frame: Day 0, 7, 8 and 14 if applicable
|
Evaluation of the safety and tolerability of the investigational device versus comparator
|
Day 0, 7, 8 and 14 if applicable
|
Subject reported perceived acceptability, effectiveness and subjective evaluation assessed via questionnaire data
Time Frame: Day 7 or Day14
|
Evaluation of the perceived acceptability, effectiveness and subjective evaluation. Subject perception questionnaire with the following scale items: totally agree agree rather agree rather disagree disagree |
Day 7 or Day14
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20E4084
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head Lice
-
Taro Pharmaceuticals USACompletedLice; Head LiceUnited States
-
Topaz Pharmaceuticals IncCompletedPediculus Humanus Capitis (Head Lice)United States
-
Dr. Reddy's Laboratories LimitedCompleted
-
Infectopharm Arzneimittel GmbHRecruitingPediculosis Capitis | Head Lice Infestation | LiceGermany
-
Dr. Reddy's Laboratories LimitedTKL Research, Inc.; AccelovanceCompletedHead LiceUnited States
-
Topaz Pharmaceuticals IncCompleted
-
Dr. Reddy's Laboratories LimitedSyneos Health; AccelovanceCompletedHead Lice InfestationUnited States
-
Alliance PharmaceuticalsSouth Florida Family Health and Research CentersRecruitingHead Lice | Lice Infestations | Pediculosis CapitisUnited States
-
Perrigo CSCIRecruitingHead Lice InfestationMauritius
-
Boston Scientific CorporationCompletedHead Lice | Pediculus Humanus CapitisUnited States
Clinical Trials on INVESTIGATIONAL DEVICE
-
Coloplast A/SCompleted
-
NanoVationCompletedChronic Obstructive Pulmonary Disease (COPD)Israel
-
Cutera Inc.CompletedPigmented Skin Lesion of Suspected Benign NatureUnited States
-
University at BuffaloUniversity at Buffalo Jacobs InstituteRecruitingIschemic StrokeUnited States
-
Perimeter Medical ImagingCancer Prevention Research Institute of TexasCompletedBreast Cancer FemaleUnited States
-
Boston Scientific CorporationCompleted
-
Centre for Addiction and Mental HealthScion NeuroStimRecruitingSchizophrenia | AnosognosiaCanada
-
LifeNet HealthWithdrawn
-
CochlearCompletedConductive Hearing Loss | Deafness; Sensoneural Single Sided | Mixed Hearing LossAustralia
-
Avelas Biosciences, Inc.Clinipace Worldwide; RRD International, Inc.CompletedStage I Breast Cancer | Stage II Breast Cancer | Carcinoma, Ductal, Breast | Breast Cancer Female | Stage III Breast Cancer | Carcinoma Breast | Primary Invasive Malignant Neoplasm of Female BreastUnited States